GlassScriptPhysician profile
Christopher De Jesus
NPI 1184019374
$200,619.81
in general payments reported to CMS, 2019-2025
21 companies · $25K in 2025
The $25K reported for 2025 was more than what 96% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,146 · 2022: $4,002 · 2023: $63K · 2024: $105K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $170K · Food and Beverage: $12K · Travel and Lodging: $7,133 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $169,623.06 |
| Food and Beverage | $11,716.82 |
| Travel and Lodging | $7,132.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $199,125.80 | 2021-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Medtronic, INC. | $370.23 | 2022-2025 | Eea |
| Intercept Pharmaceuticals, INC. | $174.22 | 2021-2023 | Ocaliva |
| Kerecis Limited | $156.39 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Solventum Corporation | $144.28 | 2025 | V.A.C.Ulta, Prevena |
| Checkpoint Surgical, INC | $99.56 | 2024 | Checkpoint Stimulators |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.57 | 2022-2023 | Xifaxan |
| Ardelyx, INC. | $76.92 | 2022-2023 | Ibsrela |
| Redhill Biopharma INC. | $69.38 | 2022 | |
| Abbvie INC. | $68.87 | 2022-2023 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $47.30 | 2022-2023 | Entyvio |
| Ethicon US, LLC | $30.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.57 | 2023 | Cyltezo |
| Innovation Technologies INC | $22.88 | 2025 | Irrisept |
| Exact Sciences Corporation | $20.97 | 2023 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $20.75 | 2021 | |
| Baxter Healthcare | $19.68 | 2025 | Tisseel |
| Axonics, INC. | $17.81 | 2023 | Axonics |
| Vivus LLC | $17.59 | 2021 | |
| Davol INC. | $17.37 | 2025 | Surgiphor |
| Janssen Biotech, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher De Jesus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.